Navigation Links
Viral genetic differences are possible key to HIV dementia

equences from subjects with little or no cognitive deficit. "In other words," says Pillai, "there appears to be a particular HIV mutation that is associated with dementia." He cautions that this result is "suggestive, not conclusive," because of the study's small sample size.

This information "may be clinically relevant in terms of treatment," Pillai explains. "If we identify the quintessential neurotoxic variant of HIV, could we use that as a predictor of HIV dementia?" He says that such knowledge could also help care providers make "guided therapeutic decisions ?for example, the detection of particular viral genotypes may lead physicians to select for antiretroviral regimens that cross the blood-brain barrier into the CNS most efficiently." Or, he speculates, "we might actually try to design a drug to target these genetic variants that are responsible for the neurological damage."

Pillai notes that the issue of HIV dementia is particularly important in regions outside North America and Europe where state-of-the-art antiretroviral medications are not widely available and HIV infection frequently leads to dementia.

SFVAMC staff physician Joseph K. Wong, MD, associate professor of medicine at UCSF and senior author of the study, adds, "In addition to the implications of this new knowledge for the 40 million people infected with HIV, this study may also contribute to our general understanding of viral encephalitis," or brain inflammation caused by other viruses. "These results suggest that specific features of viral components themselves, and not just the immune response to viral infection, may be responsible for direct damage to the nervous system."

Pillai says that even though the study included almost 500 gene sequences, it is still exploratory: "We are now in the process of expanding this to a survey of 100 to 150 individuals."

The study's co-authors were Sergei L. Kosakovsky Pond, PhD, of UC San Diego; Yang Liu, P
'"/>

Source:University of California - San Francisco


Page: 1 2 3

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
3. Viral protein influences key cell-signaling pathway
4. Viral protein helps infected T cells stick to uninfected cells
5. Viral fitness explains different resistance patterns to aids drugs
6. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
7. Viral marker of human migration suspect
8. Viral protein is an effective preventative against infection
9. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
10. Scientists detect probable genetic cause of some Parkinsons disease cases
11. Mouse brain tumors mimic those in human genetic disorder
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Viral genetic differences are possible key HIV dementia

(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Office has granted an exclusive license of a novel ... Inc., which plans to initiate early-stage human clinical trials ... Gary Landreth, PhD, the Riuko and Archie G. Co ... PhD, co-founded ReXceptor after discovering that bexarotene (a medication ...
... and Oxford, UK Cancer cells are a problem for ... blithely metastasize to set up shop in places where they ... this way is a tumor suppressor named p53. This protein ... those that are damaged beyond repair. Not surprisingly, p53,s critical ...
... across the UK has shown a grass hybrid species ... The BBSRC-funded scientists, from Rothamsted Research, the James Hutton ... at Aberystwyth University, Lancaster University and the University of ... perennial ryegrass ( Lolium perenne ) with a closely ...
Cached Biology News:Research spinoff ReXceptor gets license for Alzheimer's treatment 2Reviving a foe of cancer 2New grass hybrid could help reduce the likelihood of flooding 2
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... that the 30-day review period following the filing ... ocular indications with the U.S. Food and Drug ... now active. Logo -  ...
(Date:8/31/2015)... , Aug. 31, 2015 FLX Bio, Inc., ... of novel cancer immunotherapies, announced today that it has ... Executive Officer and William Ho , M.D., Ph.D., ... an experienced management team led by veterans of Flexus ... Ph.D., Chief Scientific Officer; Jay Powers , Ph.D., ...
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
(Date:8/31/2015)... ... August 31, 2015 , ... Proove Biosciences, Inc. is a finalist ... Annual High Tech Awards. , Now in its 22nd year, this premier awards event ... here, across the nation and around the world. The OC Tech Alliance will announce ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 2Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 3Proove Biosciences, Inc. Named a Finalist for 22nd OC Tech Alliance High-Tech Awards for Company of the Year 4
... , , , , ... Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its first fiscal ... from the $1,394,000 reported for the same period last year. , ... compared to a net profit for the same period of the prior fiscal year ...
... , , , LEXINGTON, ... for Genome Resources (NCGR) has selected febit,s DNA-capture method, HybSelect(TM), ... of the most devastating childhood diseases with the ultimate goal ... genetic diseases in prospective parents. , , ...
... and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... that the United States Patent and Trademark Office ... entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 ... cancer drug candidate, OGX-011, to treat certain cancers. ...
Cached Biology Technology:Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 2The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3